Vancomycin dosing in neutropenic patients

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Neutropenia, a condition of low neutrophil count, can impact drug metabolism.
• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.

Purpose of the Study:

• To compare vancomycin pharmacokinetic parameters in patients with and without neutropenia.
• To determine the effect of neutropenia on vancomycin clearance and dosing requirements.

Main Methods:

• Prospective study including 171 adult patients admitted to general wards.
• Vancomycin trough and peak plasma concentrations were measured.
• Pharmacokinetic parameters were determined using Bayesian estimation.

Main Results:

• Patients with neutropenia showed significantly higher vancomycin clearance (CLva) (67 mL/min) compared to those without neutropenia (50 mL/min).
• Neutropenia was independently associated with increased CLva.
• Patients with neutropenia required approximately 33% higher vancomycin doses to achieve therapeutic AUC24 targets.

Conclusions:

• Most patients with neutropenia experience augmented vancomycin clearance.
• The increased vancomycin clearance in neutropenic patients appears reversible upon resolution of neutropenia.
• Recommendations include a one-third increase in daily vancomycin dose for neutropenic patients and frequent therapeutic drug monitoring.